Outsourcing Guide

Cont. Education

Software/Reports

Training Courses

Web Seminars

Jobs

Buyer's Guide

Home Page

Pharm Patents /
Licensing

Pharm News

Federal Register

Pharm Stocks

FDA Links

FDA Warning Letters

FDA Doc/cGMP

Pharm/Biotech Events

Consultants

  Understanding what makes key opinion leaders prefer one company’s programs over another company’s can give you a considerable edge as you design a marketing plan that includes valuable insight from these highly influential physicians.

  PharmaForce has polled hundreds of KOLs in the United States.  This report is your opportunity to find out what  KOLs across key therapeutic areas have told us about the following:

–        What companies run the best advisory boards and why

–        Acceptable honorarium levels

–        Factors KOLs consider when deciding whether or not to attend a program

–        Preferred meeting focus and structure

–        Topics of key interest  

–        Differences in perspectives of researchers vs.  clinicians

For clients interested in this same type of information on a global scale, a similar study is available on KOL perspectives in Europe.

This one-of-a-kind report captures the responses of over 100 practicing oncologists in the United States – as they are asked to rate the effectiveness of leading oncology sales forces in regard to the following attributes:
 

We not only capture the revealing survey results, but PharmaForce digs deeper by conducting targeted interviews with members of the “best” and “worst” performing sales forces to uncover the reasons for their rankings.

This program analyzes in detail the marketing expenditures of leading oncology franchises in the top five countries in Europe (i.e., France, Germany, Italy, Spain and the United Kingdom).  The key expenditures benchmarked include:

 
Analysis of the sales and marketing organizations includes:

* Save 5% -- Mention "PharmCast.com" when purchase.

To receive more information about the study, please click on the following "Request for Info" link.